The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
Authors
Keywords
-
Journal
GYNECOLOGICAL ENDOCRINOLOGY
Volume 30, Issue 6, Pages 403-408
Publisher
Informa UK Limited
Online
2014-03-05
DOI
10.3109/09513590.2014.892067
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies
- (2013) Pedro Esbrit et al. BIOCHEMICAL PHARMACOLOGY
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
- (2013) Joy N Tsai et al. LANCET
- Osteoporosis Diagnosis and Medical Treatment
- (2013) Amy H. Warriner et al. ORTHOPEDIC CLINICS OF NORTH AMERICA
- The effects of osteoclast modifiers on the oral cavity
- (2013) Matthew S. Epstein et al. Current Opinion in Supportive and Palliative Care
- Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis
- (2012) Emily E Sutton et al. ANNALS OF PHARMACOTHERAPY
- Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data
- (2012) David W. Dempster et al. CLINICAL THERAPEUTICS
- Bisphosphonates in the Treatment of Osteoporosis
- (2012) Dima L. Diab et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Early or Continued Osteoporosis Treatment During Nonvertebral Fracture-Healing: No Harm Done
- (2012) Robert J Pignolo JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
- (2012) Silvano Adami et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments
- (2012) Charles A. Inderjeeth et al. JOURNAL OF BONE AND MINERAL METABOLISM
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Incidence of atypical nontraumatic diaphyseal fractures of the femur
- (2012) Richard M Dell et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
- (2012) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis
- (2012) Michael R. McClung et al. JOURNAL OF CLINICAL DENSITOMETRY
- Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study
- (2012) Michael A. Bolognese et al. JOURNAL OF CLINICAL DENSITOMETRY
- New therapeutic targets for osteoporosis: Beyond denosumab
- (2012) Vivien Lim et al. MATURITAS
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
- (2012) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
- (2011) Pauline L Martin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review
- (2011) Mary Barna Bridgeman et al. CLINICAL THERAPEUTICS
- Effects of denosumab on fracture and bone mineral density by level of kidney function
- (2011) Sophie A Jamal et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
- (2011) Socrates Papapoulos et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
- (2011) S. Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
- (2011) N. B. Watts et al. OSTEOPOROSIS INTERNATIONAL
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
- (2011) Tim Van den Wyngaert et al. SUPPORTIVE CARE IN CANCER
- Denosumab and bisphosphonates: Different mechanisms of action and effects
- (2010) Roland Baron et al. BONE
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
- (2010) P. Garnero et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
- (2010) Ego Seeman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
- (2010) Elizabeth Shane et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
- (2010) Richard Eastell et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
- (2010) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab-related osteonecrosis of the jaws
- (2010) A. Kyrgidis et al. OSTEOPOROSIS INTERNATIONAL
- Osteonecrosis of the jaws induced by anti-RANK ligand therapy
- (2009) K.H. Taylor et al. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bisphosphonate Associated Osteonecrosis of the Jaw
- (2009) A. A. KHAN et al. JOURNAL OF RHEUMATOLOGY
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- (2008) Paul D. Miller et al. BONE
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases
- (2008) Kan Yonemori et al. CANCER SCIENCE
- Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
- (2008) Mary L Bouxsein et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*
- (2008) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
- (2008) R. G. G. Russell et al. OSTEOPOROSIS INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started